Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Exclusion Criteria

• •Must have at least one of the following considered related to disease:
• •1. Local symptoms due to progressive or bulky nodal disease.
• •2. Compromise of normal organ function due to progressive or bulky disease.
• •3. Presence of systemic B symptoms.
• •4. Presence of symptomatic extranodal disease.
• •5. Cytopenias due to extensive bone marrow infiltration, autoimmune hemolytic anemia or thrombocytopenia, or hypersplenism.
• •ECOG performance status of 0 or 1.
• •Aged 18 years or older.
• •Laboratory requirements.
• •Patients with another active cancer (excluding basal cell carcinoma or cervical intraepithelial neoplasia \[CIN/cervical in situ\] or melanoma in situ). Prior history of cancer is allowed, as long as there is no active disease.
• •Pregnant or lactating women.
• •Patients with uncontrolled intercurrent illness, active or uncontrolled infections, or a fever \>38.5 Celsius (not due to tumor fever) on the day of scheduled dosing.
• •Patients with a history of pericardial disease.
• •Patients with small, moderate or large pericardial effusions or patients with a diagnosis of pericarditis.
• •Patients with significant cardiac abnormalities.
• •Patients with serious illnesses, medical conditions, or other medical history which would be likely to interfere with patient's participation in the study or with the interpretation of the results.
• •Patients who have been treated with any investigational drug within 28 days prior to study initiation.
• •Known hypersensitivity to HDAC inhibitors and to any components of MGCD0103.
• •Known human immunodeficiency virus (HIV) or active Hepatitis B or C.
• •Central nervous system lymphoma and lymphoma involving leptomeningeal area.